摘要
目的:评价乌司他丁联合奥曲肽在重症急性胰腺炎(severe acute pancreatitis,SAP)临床治疗中的应用效果。方法:取本院2017年3月-2020年3月收治的76例SAP患者,应用单双号法分为观察组、对照组,两组均给予常规治疗,对照组在此基础上给予奥曲肽治疗,观察组在对照组的基础上联合乌司他丁治疗,比较两组治疗前后C反应蛋白(CRP)、血淀粉酶水平(AMS),以及治疗后腹痛、腹胀缓解时间和治疗总有效率、不良反应发生率情况。结果:治疗前两组CRP、AMS水平差异均无统计学意义(P>0.05),治疗后CRP、AMS水平均较治疗前下降,且观察组下降更为明显(P<0.05);观察组治疗后腹痛和腹胀缓解所用时间较对照组短(P<0.05),临床治疗总有效率优于对照组,差异均有统计学意义(P<0.05);两组治疗期间不良反应发生率差异无统计学意义(P>0.05)。结论:乌司他丁联合奥曲肽在SAP临床治疗中的应用,可进一步改善患者炎性反应,加速患者临床症状的缓解,提高疾病治疗总有效率,且安全性高。
Objective:To evaluate the effect of Ulinastatin combined with Octreotide in the treatment of severe acute pancreatitis (SAP).Method:A total of 76 SAP patients admitted to our hospital from March 2017 to March 2020 were selected and divided into the observation group and the control group by single or even number method.Both groups were given conventional treatment,while the control group was given Octreotide,the observation group was treated with Ulinastatin on the basis of the control group.Before and after treatment,the C-reactive protein (CRP),blood amylase levels (AMS),and abdominal pain were compared between the two groups.The remission time of abdominal distension,the total effective rate and the incidence of adverse reactions were analyzed between the two groups.Result:Before treatment,there were no significant differences in the levels of CRP and AMS between the two groups (P>0.05).After treatment,the levels of CRP and AMS were lower than those of the before treatment,the observation group were decreased more significantly than those of the control group (P<0.05).The time for relieving abdominal pain and abdominal distension in the observation group were shorter than those of the control group (P<0.05),and the total effective rate of clinical treatment was better than that of the control group,the differences were statistically significant (P<0.05),adverse reactions occurred in the two groups during the treatment,which had no significant difference (P>0.05).Conclusion:Ulinastatin combined with Octreotide in the clinical treatment of SAP can improve the inflammatory response of patients,accelerate the remission of clinical symptoms,improve the total efficiency of disease treatment,and it is high safety.
作者
许志毅
XU Zhiyi(Beihai Second People’s Hospital,Beihai 536000,China)
出处
《中外医学研究》
2021年第12期33-35,共3页
CHINESE AND FOREIGN MEDICAL RESEARCH
